eFFECTOR Therapeutics Statistics
Total Valuation
eFFECTOR Therapeutics has a market cap or net worth of 941. The enterprise value is -5.13 million.
| Market Cap | 941 |
| Enterprise Value | -5.13M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
eFFECTOR Therapeutics has 4.70 million shares outstanding. The number of shares has increased by 68.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.70M |
| Shares Change (YoY) | +68.04% |
| Shares Change (QoQ) | +52.87% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 5.14% |
| Float | 4.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.15 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.18 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 24.48.
| Current Ratio | 1.03 |
| Quick Ratio | 0.99 |
| Debt / Equity | 24.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.69 |
| Interest Coverage | -10.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -83.33% |
| Return on Capital (ROIC) | -111.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.47M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks. The beta is 0.62, so eFFECTOR Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 30.34 |
| Average Volume (20 Days) | 6,766 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | -21.62M |
| Operating Income | -32.70M |
| Pretax Income | -34.63M |
| Net Income | -34.63M |
| EBITDA | -32.59M |
| EBIT | -32.70M |
| Earnings Per Share (EPS) | -12.42 |
Balance Sheet
The company has 25.38 million in cash and 20.25 million in debt, giving a net cash position of 5.14 million or 1.09 per share.
| Cash & Cash Equivalents | 25.38M |
| Total Debt | 20.25M |
| Net Cash | 5.14M |
| Net Cash Per Share | 1.09 |
| Equity (Book Value) | 827,000 |
| Book Value Per Share | 0.21 |
| Working Capital | 681,000 |
Cash Flow
In the last 12 months, operating cash flow was -29.19 million and capital expenditures -84,000, giving a free cash flow of -29.28 million.
| Operating Cash Flow | -29.19M |
| Capital Expenditures | -84,000 |
| Free Cash Flow | -29.28M |
| FCF Per Share | -6.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
eFFECTOR Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.04% |
| Shareholder Yield | -68.04% |
| Earnings Yield | -6,212,192.50% |
| FCF Yield | -3,111,442.90% |
Stock Splits
The last stock split was on January 12, 2024. It was a reverse split with a ratio of 0.04.
| Last Split Date | Jan 12, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |